Invesco Ltd. Purchases 5,480 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Invesco Ltd. increased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.2% in the fourth quarter, Holdings Channel reports. The fund owned 2,555,538 shares of the biopharmaceutical company’s stock after purchasing an additional 5,480 shares during the quarter. Invesco Ltd.’s holdings in Amicus Therapeutics were worth $24,073,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at approximately $79,000. KBC Group NV boosted its position in Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,120 shares in the last quarter. Sciencast Management LP purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at $100,000. Stephens Inc. AR bought a new position in shares of Amicus Therapeutics in the 4th quarter worth $101,000. Finally, AlphaQuest LLC lifted its stake in shares of Amicus Therapeutics by 635.1% during the 4th quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 9,272 shares during the last quarter.

Amicus Therapeutics Price Performance

NASDAQ:FOLD opened at $6.83 on Friday. The firm’s fifty day moving average is $8.42 and its two-hundred day moving average is $9.52. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -37.94, a PEG ratio of 1.51 and a beta of 0.79. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics, Inc. has a one year low of $6.20 and a one year high of $12.65.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, Wells Fargo & Company decreased their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.